Leucine

Leucine has been studied in 247 papers since 2014: 52 trials and 35 observational studies in people, 28 in animals, 7 in cells, 117 reviews; 62 in the past year. Its furthest trials in people are at phase 2/3. The newest story, Oct 16, 2026: “Protein and leucine added no measurable benefit in older men”.

InterventionPhase 2/3

247 papers study it153 findingsUpdated

MeSH

Research on it is growing 46% faster than aging research as a whole: 39 papers in the latest year counted

More supplements

6 new papers in 30 daysSee all 247 papers on leucine

At a glance

Independent labs found the same change in worms or flies and people. 50 independent labs in 19 countries; 22 trials, 8 about aging, 3 with no results posted.

“We observed that leucine supplementation was ineffective to improve muscle mass and function.”
Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trialClinical nutrition (Edinburgh, Scotland)2021doi:10.1016/j.clnu.2021.06.024

16 of its findings point the other way.

Worms or flies and humans: replicated by independent labs. Cells and mice: a single group.
  • 50 independent labs in 19 countries
  • 16 findings against
  • 22 trials, 8 about aging, 3 with no results posted
  • Funders: National Institutes of Health and others
  • 18 of 135 findings with company ties
  • Human trial52
  • Humans35
  • Animals26
  • Model organisms2
  • Cells7
  • In silico3

27 studies gave leucine to people and measured what changed.

What changedDesignPeopleSource

up: Increases pS6/S6

down: Decreases LC3

Randomized trialMeal responses sampled through 3 h15 peopleadultsPatient cohortsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

no change: Has no effect on body composition

no change: Has no effect on sarcopenic outcomes

Randomized trial28 days80 peoplemen60–89 yearsOlder men aged 60–89 years with a BMI ≥ 23.0 kg/mNutrients, Oct 2, 2026

no change: Has no effect on body composition

Randomized trial28 days80 peoplemen60–89 yearsOlder men aged 60–89 years with a BMI ≥ 23.0 kg/mPreprints.org, Sep 14, 2026

no change: Has no effect on skeletal muscle

Randomized trial4 weeks80 peopleMenyoung adultDuring alternate-day fastingPreprints.org, Aug 19, 2026

up: Increases leucineP < 0.001

Randomized trial≤4 h45 peopleMen69 ± 5 yOlder adultsThe Journal of nutrition, Aug 17, 2026

What did mouse lifespan tests of leucine find?

NIA ITP

The NIA Interventions Testing Program ran 1 arm in 2017; the change in median lifespan ran from −2% to 0%.

What did other lifespan studies of leucine find?

DrugAge

DrugAge records 4 results from 2 papers: 4 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of leucine find?

98

Studies of leucine measured 98 outcomes, among them muscle strength, mTOR signaling and muscle protein synthesis.

Muscle strength

no changein humans4upin humans1upin mice1

6 studies
  1. Leucine showed no clear effect on muscle strength in humans (head and neck cancer and non-cancer).

    “Secondary outcomes, including muscle strength, gait speed, phase angle, and inflammatory markers, did not differ significantly between groups.”

    Human trialhead and neck cancer and non-cancer6 g/day4 weeksn = 41

    Short-term isolated leucine supplementation was not associated with improvements in muscle mass or function in patients with head and neck cancer: A randomized, double-blind, proof-of-concept trial with an elderly non-cancer comparator cohort

    Clinical nutrition ESPEN

  2. Leucine showed no clear effect on muscle strength in humans (alone during resistance training).

    “LC combined with leucine or leucine alone does not appear to improve the effectiveness of RET”

    Human trialalone during resistance trainingL-leucine4 g per day24 weeksfemalesn = 13

    L-Carnitine Combined with Leucine Supplementation Does Not Improve the Effectiveness of Progressive Resistance Training in Healthy Aged Women

    The journal of nutrition, health & aging

  3. Leucine showed no clear effect on muscle strength in humans (added to resistance training).

    “No additive effect of a leucine-rich amino acid supplement on muscle strength or mass was observed.”

    Human trialadded to resistance trainingleucine-rich amino acid supplement6 g daily48 weeks

    Effects of resistance training using elastic bands on muscle strength with or without a leucine supplement for 48 weeks in elderly patients with type 2 diabetes

    Endocrine journal

  4. Leucine showed no clear effect on muscle strength in humans (added to resistance training, compared with placebo).

    “there were significant increases in strength in both groups in response to RT, but not supplementation”

    Human trialadded to resistance training, compared with placebo5 g10 weeksn = 36

    Efficacy of L-leucine Supplementation Coupled With Resistance Training in Untrained Midlife Women

    Journal of the American College of Nutrition

  5. Leucine improves muscle strength in mice (SOD1G93A mice).

    “In addition, the phenotypes of reduced muscle strength and fewer NMJs of SOD1G93A mice are also improved by leucine supplementation.”

    AnimalsSOD1G93A mice

    Vcp overexpression and leucine supplementation extend lifespan and ameliorate neuromuscular junction phenotypes of a SOD1G93A-ALS mouse model

    Human molecular genetics

  6. Leucine improves muscle strength in humans (sarcopenia) (SMD = 0.794; 95% CI, 0.104-1.485; P = 0.024).

    “As the primary outcome, muscle strength improved significantly in the leucine group (SMD = 0.794; 95% CI, 0.104-1.485; P = 0.024).”

    Reviewsarcopenia

    Effects of leucine-rich protein supplements in older adults with sarcopenia: A systematic review and meta-analysis of randomized controlled trials

    Archives of gerontology and geriatrics

mTOR signaling

upin reviews4upin humans1downin mice1

6 studies
  1. Leucine activates mTOR signaling.

    “Leucine, a branched-chain amino acid, is well known for its anabolic effects mediated through mTOR activation”

    Review

    Amino Acid Regulation of Cellular Aging Pathways and Therapeutic Perspectives for Healthspan and Lifespan Enhancement

    Advances in Gerontology

  2. Leucine activates mTOR signaling in humans (most potent of all EAA; ~3-fold more than with all other EAA).

    “Of all the EAA, LEU is the most potent stimulator of the mechanistic target of rapamycin complex 1 (mTORC1)-signalling pathway”

    Review

    A focus on leucine in the nutritional regulation of human skeletal muscle metabolism in ageing, exercise and unloading states

    Clinical nutrition (Edinburgh, Scotland)

  3. Leucine activates mTOR signaling.

    “Leucine, a BCAA, and its metabolite, β-hydroxy-β-methylbutyrate (HMB), both activate mammalian target of rapamycin complex 1 (mTORC1) and increase protein synthesis”

    Reviewskeletal muscle

    Regulation of Skeletal Muscle Function by Amino Acids, Especially Non-Proteinogenic Amino Acids

    Journal of nutritional science and vitaminology

  4. Leucine inhibits mTOR signaling in mice.

    “In the liver, mTORC1 was inhibited by leucine.”

    Animalsliver

    REV-ERBα alters circadian rhythms by modulating mTOR signaling

    Molecular and cellular endocrinology

  5. Leucine activates mTOR signaling.

    “Leucine, a BCAA, and its metabolite, β-hydroxy-β-methylbutyrate (HMB), both activate mammalian target of rapamycin complex 1 (mTORC1) and increase protein synthesis”

    Review

    Regulation of Skeletal Muscle Function by Amino Acids

    Nutrients

  6. Leucine activates mTOR signaling.

    “Leucine acts as a signaling molecule directly at the muscle level via the activation of mammalian/mechanistic target of rapamycin complex 1 (mTORC1).”

    Reviewskeletal muscle

    Leucine and Mammalian Target of Rapamycin-Dependent Activation of Muscle Protein Synthesis in Aging

    The Journal of nutrition

More on mTOR signaling

muscle protein synthesis

upin reviews4upin humans2

6 studies
  1. Leucine activates muscle protein synthesis.

    “The review highlights the importance of leucine and other amino acids in promoting muscle protein synthesis”

    Review

    Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets

    Canadian journal of physiology and pharmacology

  2. Leucine increases muscle protein synthesis (meals with at least 2.8 g leucine in older adults (>60 years)) (at least 2.8 g leucine (~30 g protein) per meal).

    “Clinical studies demonstrated that older adults (>60 years) require meals with at least 2.8 g of leucine (~30 g of protein) to stimulate MPS.”

    Reviewmeals with at least 2.8 g leucine in older adults (>60 years)at least 2.8 g leucine per meal

    Impacts of protein quantity and distribution on body composition

    Frontiers in nutrition

  3. Leucine increases muscle protein synthesis in humans.

    “the branch chain amino acid leucine can trigger and enhance MPS in older adults”

    Reviewskeletal muscle

    mTOR1c Activation with the Leucine "Trigger" for Prevention of Sarcopenia in Older Adults During Lockdown

    Journal of medicinal food

  4. Leucine increases muscle protein synthesis.

    “it acts independently of growth factors and leads to enhanced cap-dependent mRNA translation initiation and increased protein synthesis.”

    Reviewskeletal muscle

    Leucine and Mammalian Target of Rapamycin-Dependent Activation of Muscle Protein Synthesis in Aging

    The Journal of nutrition

  5. Leucine increases muscle protein synthesis.

    “Leucine and arginine play important roles in muscle protein synthesis and cell growth”

    Reviewskeletal muscle

    Amino acids in healthy aging skeletal muscle

    Frontiers in bioscience (Elite edition)

  6. Leucine increases muscle protein synthesis in older individuals.

    “Nutritional strategies such as leucine supplementation, use of fast digested proteins or a pulse protein intake have been show to enhance the synthesis rate of muscle proteins in older individuals.”

    Reviewin older individuals

    Ornithine alpha-ketoglutarate: could it be a new therapeutic option for sarcopenia?

    The journal of nutrition, health & aging

Sarcopenia

no changein humans2downin humans2

3 studies
  1. Leucine was not clearly linked with sarcopenia in humans (adjusted for age, BMI, total protein and total energy intake).

    “neither leucine nor total polyphenol intake showed independent associations with sarcopenia.”

    Humansadjusted for age, BMI, total protein and total energy intake

    Dietary Leucine and Total Polyphenol Intake and Their Associations with Sarcopenia Indicators Among Older People Participating in the Program for Complementary Food in Older People (PACAM) in the Metropolitan Region, Santiago de Chile

    Nutrients

  2. Leucine decreases sarcopenia in humans (paired with protein supplements, with or without physical exercise).

    “Leucine supplementation, specifically paired with protein supplements, both with and without physical exercise, was found to be an effective dietary intervention for the improvement of sarcopenia.”

    Reviewpaired with protein supplements, with or without physical exercise

    Effect of supplementation with leucine alone, with other nutrients or with physical exercise in older people with sarcopenia: a systematic review

    Endocrinologia, diabetes y nutricion

  3. Leucine showed no clear effect on sarcopenia in humans (without physical exercise).

    “leucine supplementation alone and without physical exercise did not improve markers of sarcopenia”

    Reviewwithout physical exercise

    Effect of supplementation with leucine alone, with other nutrients or with physical exercise in older people with sarcopenia: a systematic review

    Endocrinologia, diabetes y nutricion

  4. Leucine decreases sarcopenia in humans.

    “significantly improves sarcopenia in elderly individuals, mainly by improving lean muscle-mass content”

    Reviewleucine or leucine-enriched protein1.2-6 g leucine/day

    Beneficial Effects of Leucine Supplementation on Criteria for Sarcopenia: A Systematic Review

    Nutrients

More on Sarcopenia

Handgrip strength

upin humans2no changein humans1

3 studies
  1. Leucine improves handgrip strength in humans (combined with exercise versus exercise alone; responder rate).

    “The intervention group showed higher responder rates for handgrip strength and gait speed compared with the exercise-only group”

    Human trialcombined with exercise versus exercise alone; responder ratebeverage and capsule6 g/day12 weeksn = 24

    Combined leucine supplementation and exercise to counteract sarcopenia in patients with end-stage kidney disease undergoing maintenance hemodialysis: a single-center randomized pilot study

    Kidney research and clinical practice

  2. Leucine improves handgrip strength in humans (sarcopenia) (p = 0.03).

    “Patients receiving leucine and patients receiving a placebo had significantly different handgrip (p = 0.03), appendicular skeletal muscle mass/height2 (p = 0.0.2), and gait speed (p = 0.008).”

    Reviewsarcopenia

    Effects of Leucine Supplementation in Older Adults with Sarcopenia: A Meta-Analysis

    Nutrients

  3. Leucine showed no clear effect on handgrip strength in humans (WMD = 1.23 kg, 95% CI: -0.58, 3.03, P = 0.183).

    “handgrip strength (WMD = 1.23 kg, 95% CI: -0.58, 3.03, P = 0.183) and leg press (WMD = -1.35 kg, 95% CI: -7.46, 4.77, P = 0.666).”

    Review

    The Effect of Leucine Supplementation on Sarcopenia-Related Measures in Older Adults: A Systematic Review and Meta-Analysis of 17 Randomized Controlled Trials

    Frontiers in nutrition

MTOR

upin humans1upin mice1upin reviews1

3 studies
  1. Leucine activates MTOR.

    “the discovery of the unique role of leucine for the activation of the mTOR signal complex for the initiation of MPS”

    Review

    Impacts of protein quantity and distribution on body composition

    Frontiers in nutrition

  2. Leucine activates MTOR in humans.

    “l-leucine activates TOR to initiate protein synthesis in the skeletal muscle.”

    Reviewskeletal muscle

    The effects of glucagon and the target of rapamycin (TOR) on skeletal muscle protein synthesis and age-dependent sarcopenia in humans

    Clinical nutrition ESPEN

  3. Leucine activates MTOR in 13-month-old mice.

    “both 8 weeks of leucine supplementation and aerobic training elevated the activity of mTOR”

    Animalsin 13-month-old micechow diet with 5% leucineskeletal muscle5% leucine in chow8 weeks

    Hypertrophy-Promoting Effects of Leucine Supplementation and Moderate Intensity Aerobic Exercise in Pre-Senescent Mice

    Nutrients

More on MTOR

Muscle mass

no changein humans2upin humans1

2 studies
  1. Leucine showed no clear effect on muscle mass in humans with resistance exercise.

    “while SMI did not significantly change over 24 weeks (from 9.2 ± 2.5 to 9.2 ± 2.3 kg/m2, p = 0.851”

    Human trialwith resistance exercise12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  2. Leucine increases muscle mass in humans (hemodialysis patients) (14 patients (63.6%)).

    “After 12 weeks of intervention, skeletal muscle index was increased in 14 patients (63.6%), and grip strength was improved in 7 patients (31.8%).”

    Human trialhemodialysis patients12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  3. Leucine showed no clear effect on muscle mass in humans.

    “No other significant treatment effects were found.”

    Human trial12 monthsn = 145

    Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial

    Journal of cachexia, sarcopenia and muscle

  4. Leucine showed no clear effect on muscle mass in humans (sarcopenia) (-0.3 kg (95%CI -1.0 to 0.4), P = 0.47).

    “No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect -0.3 kg (95%CI -1.0 to 0.4), P = 0.47].”

    Human trialsarcopeniaoral powder2.5 g thrice daily12 months

    Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial

    Journal of cachexia, sarcopenia and muscle

Gait speed

upin humans2

2 studies
  1. Leucine improves gait speed in humans with resistance exercise (from 1.35 ± 0.20 to 1.41 ± 0.21 m/s).

    “In average of total patients in each time point, gait speed was the only parameter that showed improvement during the non-interventional period, with the average gait speed increased from 1.35 ± 0.20 to 1.41 ± 0.21 m/s (p = 0.04).”

    Human trialwith resistance exercise12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  2. Leucine improves gait speed in humans (hemodialysis patients) (13 patients (59.1%)).

    “In SPPB study, gait speed and sit-to-stand time was improved in 13 patients (59.1%) and 14 patients (63.6%), respectively.”

    Human trialhemodialysis patients12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  3. Leucine improves gait speed in humans (sarcopenia) (p = 0.008).

    “Patients receiving leucine and patients receiving a placebo had significantly different handgrip (p = 0.03), appendicular skeletal muscle mass/height2 (p = 0.0.2), and gait speed (p = 0.008).”

    Reviewsarcopenia

    Effects of Leucine Supplementation in Older Adults with Sarcopenia: A Meta-Analysis

    Nutrients

Grip strength

upin humans2no changein humans1

2 studies
  1. Leucine showed no clear effect on grip strength in humans with resistance exercise (32.8 ± 9.9 to 32.8 ± 8.8 kg).

    “The average HGS remained unchanged during the first 12 weeks (32.8 ± 9.9 to 32.8 ± 8.8 kg, p = 0.915) but decreased during the second 12 weeks (from 32.8 ± 8.8 to 32.0 ± 9.4 kg, p = 0.060), reflecting the low HGS response rate during non-interventional period (4.5%).”

    Human trialwith resistance exercise12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  2. Leucine improves grip strength in humans (hemodialysis patients) (7 patients (31.8%)).

    “After 12 weeks of intervention, skeletal muscle index was increased in 14 patients (63.6%), and grip strength was improved in 7 patients (31.8%).”

    Human trialhemodialysis patients12 weeksn = 22

    Leucine-enriched amino acid supplementation and exercise to prevent sarcopenia in patients on hemodialysis: a single-arm pilot study

    Frontiers in nutrition

  3. Leucine is linked with better grip strength in humans (β = 1.33 ± 0.23, p < 0.05).

    “Grip strength increased (p < 0.05) with increasing quartiles of TP, AP, PP, and leucine among all adults 19 + years (β = 1.340.19, 1.27 ± 0.19, 0.76 ± 0.20, and 1.33 ± 0.23, respectively)”

    Humans

    Association of Dietary Protein Intake and Grip Strength Among Adults Aged 19+ Years: NHANES 2011-2014 Analysis

    Frontiers in nutrition

Muscle health

upin humans1upin mice1

2 studies
  1. Leucine improves muscle health in humans (combined with resistance training or gut microbiota-targeted interventions).

    “However, its benefits emerge when combined with resistance training, or gut microbiota-targeted interventions.”

    Reviewcombined with resistance training or gut microbiota-targeted interventions

    Dietary leucine intake and sarcopenia: from isolated supplementation to combined strategies

    Current opinion in clinical nutrition and metabolic care

  2. Leucine improves muscle health in mice (aging).

    “High dose of leucine supplementation could promote skeletal muscle health in aging mice via regulating AMPKα/SIRT1/PGC-1α.”

    Animalsagingoral gavagequadriceps1,250 mg/kg·d12 weeksmalesn = 12

    Pyruvate Might Bridge Gut Microbiota and Muscle Health in Aging Mice After Chronic High Dose of Leucine Supplementation

    Frontiers in medicine

skeletal muscle protein synthesis

upin humans1no changein humans1

2 studies
  1. Leucine showed no clear effect on skeletal muscle protein synthesis in humans during 14 d of bed rest (MPS -10% ± 10% (LEU) vs -30% ± 9% (CON); no group × time interaction).

    “no differences between groups with respect to pre-post changes (group × time interactions) were detected for MPS or cell signaling”

    Human trialduring 14 d of bed restskeletal muscle0.06 g ∙ kg(-1) ∙ meal(-1)14 dn = 19

    Leucine partially protects muscle mass and function during bed rest in middle-aged adults

    The American journal of clinical nutrition

  2. Leucine improves skeletal muscle protein synthesis in humans (Compared with the leucine RDA of 42 mg/kg body weight).

    “the RDA of 42 mg/kg body weight is significantly less than the 100-110 mg/kg required to optimize metabolic regulation and skeletal muscle protein synthesis.”

    ReviewCompared with the leucine RDA of 42 mg/kg body weightskeletal muscle100–110 mg/kg body weight

    Optimizing Adult Protein Intake During Catabolic Health Conditions

    Advances in nutrition (Bethesda, Md.)

Appendicular skeletal muscle mass index

no changein humans1upin humans1

1 study
  1. Leucine showed no clear effect on appendicular skeletal muscle mass index in humans (head and neck cancer).

    “No significant between-group differences were observed in HNC patients.”

    Human trialhead and neck cancer6 g/day4 weeksn = 23

    Short-term isolated leucine supplementation was not associated with improvements in muscle mass or function in patients with head and neck cancer: A randomized, double-blind, proof-of-concept trial with an elderly non-cancer comparator cohort

    Clinical nutrition ESPEN

  2. Leucine increases appendicular skeletal muscle mass index in humans (non-cancer) (Δ 0.31 ± 0.13 vs. 0.08 ± 0.19 kg/m2, p = 0.01).

    “Leucine supplementation was associated with a modest increase in ASMMI in the non-cancer leucine group compared with its comparator (Δ 0.31 ± 0.13 vs. 0.08 ± 0.19 kg/m2; p = 0.01).”

    Human trialnon-cancer6 g/day4 weeksn = 18

    Short-term isolated leucine supplementation was not associated with improvements in muscle mass or function in patients with head and neck cancer: A randomized, double-blind, proof-of-concept trial with an elderly non-cancer comparator cohort

    Clinical nutrition ESPEN

Frailty

no changein humans1

1 study
  1. Leucine showed no clear effect on frailty in humans (Cohen’s d: 0.04, p = 0.316).

    “Mixed design analysis of variance showed that there was no significant interaction (p = 0.631) of time with treatment group for FI.”

    Human trialpowder13 weeksn = 41

    Can Leucine Supplementation Improve Frailty Index Scores?

    Geriatrics (Basel, Switzerland)

  2. Leucine showed no clear effect on frailty in humans (nursing home residents without dementia; compared with placebo) (Cohen's d: 0.04; p = 0.316).

    “This pilot study showed that a nutritional supplementation with leucine did not significantly modify the frailty index in older nursing home residents.”

    Human trialnursing home residents without dementia; compared with placebo6 g/day13 weeksmale and femalesn = 50

    Can Leucine Supplementation Improve Frailty Index Scores?

    Geriatrics (Basel, Switzerland)

Short Physical Performance Battery score

no changein humans1

1 study
  1. Leucine showed no clear effect on short Physical Performance Battery score in humans.

    “No significant treatment effect was seen in unadjusted or adjusted analyses; the point estimate of effect in adjusted analyses was close to zero although the confidence intervals do not exclude an effect size consistent with a clinically important difference of 1.0 point.”

    Human trial12 monthsn = 145

    Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial

    Journal of cachexia, sarcopenia and muscle

  2. Leucine showed no clear effect on short Physical Performance Battery score in humans (sarcopenia) (0.1 point (95%CI -1.0 to 1.1), P = 0.90).

    “Leucine did not improve the primary outcome [adjusted treatment effect 0.1 point (95%CI -1.0 to 1.1), P = 0.90].”

    Human trialsarcopeniaoral powder2.5 g thrice daily12 months

    Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial

    Journal of cachexia, sarcopenia and muscle

LC3

downin humans1

1 study
  1. Leucine decreases LC3 in humans (Compared with plant protein).

    “LC3 was preserved after plant protein but reduced after animal protein and plant plus leucine.”

    Human trialCompared with plant proteinAdded to plant proteinCD14+ monocyten = 15

    Dietary Leucine and Cholesterol Drive Atherogenic Monocyte Dysfunction: Evidence from Human Clinical Studies

    AHA Scientific Sessions 2026 abstract

More on LC3

All 98

What is leucine linked with?

16

Studies link leucine with 16 measures, most often sarcopenia (3 studies).

Sarcopenia

downin humans2upin humans1OR 0.121

3 studies
  1. Leucine is linked with a higher risk of sarcopenia in humans.

    “highest tertile of leucine, glutamate, cystine, and tyrosine intake was associated with increased risk of sarcopenia”

    Humans

    Association between dietary intake of protein and amino acids and sarcopenia: a cross-sectional study

    PloS one

  2. Leucine is linked with a lower risk of sarcopenia in humans (free-living community-dwelling) (OR: 0.121, 95% CI: 0.045-0.327, p < 0.001).

    “increased intake of leucine (OR: 0.121, 95% CI: 0.045-0.327, p < 0.001)”

    Humansfree-living community-dwellingn = 367

    Association between dietary animal-derived branched-chain amino acids and sarcopenia in older adults: a cross-sectional study based on Chinese community

    Frontiers in nutrition

  3. Leucine is linked with a lower risk of sarcopenia in humans.

    “Multivariate analysis revealed that high levels of leucine, methionine, threonine, histidine, aspartic acid, calcium, zinc, and vitamin C were associated with a lower risk of sarcopenia.”

    Humansn = 1,001

    Associations of nutritional intake and inflammatory factors with sarcopenia in community-dwelling older adults: a cross-sectional study

    European geriatric medicine

More on Sarcopenia

HDL cholesterol

no changein humans1

1 study
  1. Leucine is associated with HDL cholesterol in humans during alternate day fasting.

    “There were no significant interaction effects for any health measure (p = 0.111–0.909), except for DBP (p = 0.016) and HDL cholesterol (p = 0.013), while SBP trended towards a significant interaction (p = 0.061).”

    Human trialduring alternate day fasting28 daysmalesn = 80

    Effects of Body-Mass-Scaled Protein and Leucine Supplementation on Body Composition and Cardiometabolic Blood Markers during Weight Loss in Older Men—A Randomized Controlled Trial

    Preprints.orgPreprint

More on HDL cholesterol

Hypertension

upin humans1HR 1.94

1 study
  1. Leucine is linked with a higher risk of hypertension in humans (HR = 1.94; 95% CI 1.10–3.41).

    “leucine (HR = 1.94; 95% CI 1.10–3.41) intake and hypertension incidence among adults aged 30–39 years”

    Humans

    Hypertension incidence according to branched-chain amino acid intake in Brazilian adults: a six-year follow-up of the CUME study

    European journal of nutrition

More on Hypertension

Hand grip strength

upin humans1

1 study
  1. Leucine is associated with hand grip strength in humans (P < .05).

    “acetoacetate levels, plasma isobutyrylcarnitine (C4) levels in chronic kidney disease and leucine and hand grip strength (right)”

    Humans

    Causal relationship between branched-chain amino acids and their metabolites and frailty: A two-sample Mendelian randomization study

    Medicine

Skeletal muscle fat

downin humans1

1 study
  1. Leucine is associated with skeletal muscle fat in humans (accounting for overall protein and energy) (β = -0.63%, [-1.27%, 0.01%], p = 0.054).

    “specific essential amino acids were tentatively associated with lower muscle fat, e.g. leucine (β=-0.63%, [-1.27%,0.01%]; p = 0.054).”

    Humansaccounting for overall protein and energyhabitual intakeskeletal musclen = 294

    Association of habitual diet with skeletal muscle composition in a cross-sectional, population-based imaging study

    Nutrition journal

Multiple chronic conditions

downin humans1OR 0.506

1 study
  1. Leucine is linked with a lower risk of multiple chronic conditions in humans (OR = 0.506,95%CI:0.309,0.830).

    “between leucine (OR = 0.506,95%CI:0.309,0.830) and MCCs were significant in women, but not in men.”

    Humansfemales

    Association between dietary branched-chain amino acids and multiple chronic conditions among older adults in Chinese communities

    Nutrition & metabolism

More on Multiple chronic conditions

Parkinson's disease

downin humans1OR 0.628

1 study
  1. Leucine is linked with a lower risk of Parkinson's disease in humans (decreased to 63% per SD; IVW OR 0.628 [0.467, 0.843]; FDR = 0.021).

    “PD risk was decreased to 63% per SD. increase of circulating Leu levels”

    Humans1 SD increase in circulating levels

    The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study

    Journal of neurochemistry

More on Parkinson's disease

Muscle protein synthesis rates

upin humans1

1 study
  1. Leucine is associated with muscle protein synthesis rates in humans (r2 = 0.64, p = 0.02).

    “Ingested leucine dose was associated with the magnitude of the MPS response in older, but not younger, adults over acute (0-2 h, r2 = 0.64, p = 0.02)”

    Review

    Association of postprandial postexercise muscle protein synthesis rates with dietary leucine: A systematic review

    Physiological reports

More on Muscle protein synthesis rates

Frailty

downin humans1HR 0.63

1 study
  1. Leucine is linked with a lower risk of frailty in humans (highest vs lowest tertile (107.4-372.5 vs 35.5-89.0 mg/kg/d)) (HR 0.63, 95% CI 0.41-0.96).

    “and of frailty (0.63 [0.41-0.96], p trend: .03].”

    Humanshighest vs lowest tertile (107.4-372.5 vs 35.5-89.0 mg/kg/d)n = 2,956

    Leucine Intake and Risk of Impaired Physical Function and Frailty in Older Adults

    The journals of gerontology. Series A, Biological sciences and medical sciences

Impaired lower-extremity function

downin humans1HR 0.7

1 study
  1. Leucine is linked with a lower risk of impaired lower-extremity function in humans (highest vs lowest tertile (107.4-372.5 vs 35.5-89.0 mg/kg/d)) (HR 0.70, 95% CI 0.53-0.93).

    “those in the highest tertile (107.4-372.5 mg/kg/d) had a lower risk of ILEF (fully adjusted hazard ratio [95% confidence interval]: 0.70 [0.53-0.93], p trend: .01)”

    Humanshighest vs lowest tertile (107.4-372.5 vs 35.5-89.0 mg/kg/d)n = 2,956

    Leucine Intake and Risk of Impaired Physical Function and Frailty in Older Adults

    The journals of gerontology. Series A, Biological sciences and medical sciences

All 16

Has leucine been tested in people?

8 of 22 about aging

Yes: 52 trials and 35 observational studies in people have been published, and 22 trials are registered.

Every condition in trials

All 20

Stopped

Trial sponsors

Funding

5 grants since 2016

National Institute on Aging$2.3MNational Institute of Diabetes and Digestive and Kidney Diseases$181KJapan Society for the Promotion of Science¥6.5M

Latest

Dec 2025: 4Jan 2026: 7Feb 2026: 6Mar 2026: 5Apr 2026: 5May 2026: 3Jun 2026: 2Jul 2026: 8Aug 2026: 7Sep 2026: 5Oct 2026: 7Nov 2026: 261 papers in 12 months
Nutrients

Protein and leucine added no measurable benefit in older men

In a 28-day randomized trial of 61 older men, extra protein or leucine added no measurable benefit overall during alternate-day fasting.In a 28-day randomized trial of 61 older men, extra protein or leucine added no measurable benefit overall during alternate-day fasting.

Randomized trial · 61 peopleLeucine

See all 247 papers on leucine